Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Cancer Biological Therapy Market was valued at USD 112.08 Billion in 2024, and is expected to reach USD 147.92 Billion by 2030, rising at a CAGR of 7.69%. The global cancer biological therapy market refers to the rapidly evolving field of cancer treatment that utilizes biological agents, such as monoclonal antibodies, cytokines, and vaccines, to target and combat cancer cells. This market has witnessed significant growth and innovation over the years due to advances in biotechnology and a growing understanding of the molecular mechanisms underlying cancer.

As the understanding of cancer genetics deepens, personalized medicine approaches are being employed to tailor cancer biological therapies to individual patients, optimizing treatment outcomes. The surge in cancer cases has prompted an increase in clinical trials for novel biological therapies. Regulatory agencies have also streamlined approval processes to expedite promising treatments to patients, further facilitating market growth. The global cancer biological therapy market is expanding beyond traditional markets, with emerging economies in Asia, Latin America, and the Middle East witnessing rapid growth. Improved healthcare infrastructure and increasing awareness of advanced cancer treatments are contributing to this expansion.

Key Market Drivers

Rising Cancer Incidence

Cancer has long been one of humanity's most formidable adversaries, affecting millions of lives across the globe. Recent years have witnessed a troubling surge in cancer incidence rates, with the disease becoming an ever-increasing public health concern. Paradoxically, this ominous trend has also created an environment ripe for innovation and advancement in the field of cancer treatment, particularly in the realm of cancer biological therapies. According to data from the World Health Organization (WHO), the incidence of cancer has been steadily climbing, with millions of new cases diagnosed each year. In May 2022, the United Kingdom secured an $11.4 million grant to sustain its ongoing cancer research efforts.This upward trajectory is driven by a combination of factors, including an aging population, lifestyle changes, environmental factors, and improved cancer detection methods.

Key Market Challenges

High Costs and Accessibility

One of the significant barriers to the widespread adoption of biological therapies for cancer is their high cost. The development, production, and administration of these treatments are inherently expensive due to their complexity and the specialized nature of the technologies involved. Biological therapies, such as immunotherapies and targeted therapies, often require extensive research and clinical trials before they can be approved, further driving up costs. The manufacturing processes for these treatments, which often involve biologic agents like monoclonal antibodies or CAR-T cells, require highly sophisticated facilities and expertise, contributing to their high price tags.

For patients, the cost of these therapies can be prohibitive, especially in regions without comprehensive health insurance coverage. Even with insurance, co-pays, and out-of-pocket expenses can place a significant financial burden on families. This issue is exacerbated in low- and middle-income countries where healthcare infrastructure may be limited, and access to advanced treatments is scarce. The disparities in access to life-saving cancer therapies are glaring, creating a gap between wealthier populations who can afford cutting-edge treatments and those who cannot.

The global challenge of ensuring equitable access to these therapies requires concerted efforts from governments, pharmaceutical companies, and healthcare providers. Policy interventions, such as price regulation, subsidies, and international collaborations to reduce costs, could help mitigate these disparities. Initiatives like patient assistance programs or public health campaigns aimed at increasing awareness of available treatments may further address these challenges. Until such systemic solutions are in place, the high cost and limited accessibility of cancer biological therapies will remain a critical issue, preventing many patients from benefiting from potentially life-saving treatments.

Key Market Trends

Growing Immunotherapy Revolution

Immunotherapy, a groundbreaking approach to cancer treatment, has ignited a revolution in the field of oncology. This remarkable advancement harnesses the body's immune system to fight cancer cells, providing hope to patients and transforming the landscape of cancer care. Immunotherapy represents a paradigm shift in cancer treatment. Unlike traditional therapies like chemotherapy and radiation, which directly target cancer cells, immunotherapy focuses on strengthening the body's own defenses against cancer. It stimulates the immune system to recognize and destroy cancer cells, offering several advantages.

Immunotherapy is highly precise. It targets only cancer cells while sparing healthy tissues, minimizing side effects. Some immunotherapies can induce durable responses, with the potential for sustained remission or even cures. Immunotherapy has expanded the arsenal of treatment options, particularly for advanced and hard-to-treat cancers. Immunotherapy has demonstrated efficacy in various cancer types, including melanoma, lung, bladder, and kidney cancers, among others. As research continues, the potential applications of immunotherapy are expected to grow, widening its reach in the market.

Checkpoint inhibitors are a class of immunotherapies that block proteins that inhibit the immune response, allowing the immune system to recognize and attack cancer cells. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have achieved remarkable success in clinical trials and have been approved for multiple indications, fueling market growth. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to express chimeric antigen receptors (CARs), which can recognize and target cancer cells. CAR-T therapies have shown exceptional results in treating certain blood cancers, such as leukemia and lymphoma. for instance, On November 16, 2023, the Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, Inc.) for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

Key Market Players

• F Hoffmann-La Roche Ltd
• Novartis AG
• Merck KgAa
• Amgen Inc
• GSK PLC
• Celgene Corp
• Pfizer Inc
• Zydus Lifesciences Ltd
• Sun Pharmaceutical Industries Ltd
• Bayer AG

Report Scope:

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biological Therapy Market, By Product:

• Cancer Growth Blockers
• Monoclonal Antibodies
• Vaccines

Cancer Biological Therapy Market, By Distribution Channel:

• Hospitals
• Retail & Mail Order Pharmacies

Cancer Biological Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.